Virbac: 'strategic' acquisition of Sasaeah in Japan
According to Virbac, this strategic acquisition will give the company a leading position in the farm animal vaccine market in Japan, particularly in the cattle segment, and a broad portfolio of pharmaceutical products for all major species.
Formed by the merger of two long-standing players in the animal health sector (Fujita Pharmaceutical Co. Ltd. and Kyoto Biken Laboratories Inc.) under the aegis of ORIX Corporation, Sasaeah generates annual revenues of around €75 million, of which around 50% comes from vaccines.
Details of the transaction were not disclosed.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction